CDK5 and type 2 diabetes mellitus: While our study demonstrates promising neuroprotective and antidiabetic effects of Cdk5 inhibitor, BLINK11, over a 20-day treatment period, it does not fully capture the chronic and progressive nature of T2D-associated neurodegeneration.